Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Treatment-Resistant MDD
NCT05381974Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoints: Massachusetts General Hospital Rumination Questionnaire at 12 weeks, Resting-State Functional Connectivity at 12 weeks and 2 more. Planned start Sep 2022; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05381974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381974.